|
|
Volumn 335, Issue 7611, 2007, Pages 122-123
|
|
No cure no cost
a
a
NONE
|
|
Author keywords
[No Author keywords available]
|
|
Indexed keywords
BORTEZOMIB;
ESOMEPRAZOLE;
HYPOCHOLESTEROLEMIC AGENT;
ANTINEOPLASTIC AGENT;
BORONIC ACID DERIVATIVE;
PYRAZINE DERIVATIVE;
BONE MARROW TRANSPLANTATION;
CLINICAL TRIAL;
COST EFFECTIVENESS ANALYSIS;
DRUG COST;
DRUG EFFICACY;
DRUG MANUFACTURE;
DRUG MARKETING;
GOVERNMENT;
HEALTH CARE POLICY;
HEALTH CARE SYSTEM;
HUMAN;
MULTIPLE MYELOMA;
PATIENT COMPLIANCE;
PRIORITY JOURNAL;
PROSPECTIVE PRICING;
REIMBURSEMENT;
SHORT SURVEY;
ARTICLE;
BEHAVIORAL RESEARCH;
DRUG INDUSTRY;
ECONOMICS;
MARKETING;
NATIONAL HEALTH SERVICE;
PUBLIC RELATIONS;
REMISSION;
TREATMENT FAILURE;
UNITED KINGDOM;
ANTINEOPLASTIC AGENTS;
BEHAVIORAL RESEARCH;
BORONIC ACIDS;
DRUG COSTS;
DRUG INDUSTRY;
GREAT BRITAIN;
HUMANS;
INTERPROFESSIONAL RELATIONS;
MARKETING;
MULTIPLE MYELOMA;
PYRAZINES;
REMISSION INDUCTION;
STATE MEDICINE;
TREATMENT FAILURE;
|
|
EID: 34447642513
PISSN: 09598146
EISSN: None
Source Type: Journal
DOI: 10.1136/bmj.39267.432153.94 Document Type: Short Survey |
|
Times cited : (6)
|
|
References (1)
|
